- Home
- JANX vs HCM Comparison
JANX vs HCM Comparison
Compare JANX & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- HCM
- Stock Information
- Founded
- JANX 2017
- HCM 2000
- Country
- JANX United States
- HCM Hong Kong
- Employees
- JANX N/A
- HCM N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- JANX Health Care
- HCM Health Care
- Exchange
- JANX Nasdaq
- HCM Nasdaq
- Market Cap
- JANX 2.2B
- HCM 2.3B
- IPO Year
- JANX 2021
- HCM N/A
- Fundamental
- Price
- JANX $36.01
- HCM $16.11
- Analyst Decision
- JANX Strong Buy
- HCM Hold
- Analyst Count
- JANX 11
- HCM 1
- Target Price
- JANX $83.09
- HCM $19.00
- AVG Volume (30 Days)
- JANX 821.6K
- HCM 71.4K
- Earning Date
- JANX 03-07-2025
- HCM 03-19-2025
- Dividend Yield
- JANX N/A
- HCM N/A
- EPS Growth
- JANX N/A
- HCM N/A
- EPS
- JANX N/A
- HCM N/A
- Revenue
- JANX $13,049,000.00
- HCM $610,806,000.00
- Revenue This Year
- JANX $39.66
- HCM N/A
- Revenue Next Year
- JANX N/A
- HCM $15.89
- P/E Ratio
- JANX N/A
- HCM N/A
- Revenue Growth
- JANX 54.12
- HCM N/A
- 52 Week Low
- JANX $14.68
- HCM $12.84
- 52 Week High
- JANX $71.71
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- JANX 34.78
- HCM 68.69
- Support Level
- JANX $36.13
- HCM $13.58
- Resistance Level
- JANX $38.13
- HCM $13.96
- Average True Range (ATR)
- JANX 2.52
- HCM 0.31
- MACD
- JANX 0.08
- HCM 0.34
- Stochastic Oscillator
- JANX 5.71
- HCM 89.84
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.